ArticleMolecules (Basel, Switzerland)2026
Xanthoxylin Protects Against Alcoholic Liver Injury via the EGFR/AKT Pathway: A Combined In Silico and In Vitro Study.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alcoholic liver injury (ALI) represents a significant global health burden with limited therapeutic options. Xanthoxylin, a natural flavonoid compound, has demonstrated potential hepatoprotective properties, yet its underlying molecular mechanisms against ALI remain poorly elucidated. This study employed an integrated strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulations, and in vitro experimental validation to systematically investigate the protective mechanisms of xanthoxylin against ALI. Network pharmacology screening identified 52 intersection targets between xanthoxylin and ALI, with the top 10 core targets comprising ALB, PPARG, BCL2, PTGS2, ESR1, HIF1A, EGFR, HSP90AA1, GSK3B, and PARP1. GO enrichment analysis highlighted mitochondrion and mitochondrial outer membrane among the top 10 cellular component (CC) terms. KEGG pathway analysis revealed PI3K-Akt signaling within the top 10 pathways. Molecular docking suggested potential binding of xanthoxylin to the key targets. Subsequent MD simulations further confirmed the formation of stable complexes between xanthoxylin and EGFR, PPARG, and PTGS2. In vitro, xanthoxylin significantly ameliorated ethanol-induced HepG2 cell injury, attenuated TC and TG elevations, suppressed mitochondrial ROS accumulation, and enhanced SOD activity. Mechanistically, xanthoxylin upregulated HSP90, p-EGFR, EGFR, p-AKT, AKT, and PPARG protein expression, and suppressed the expression levels of PTGS2. Erlotinib, an EGFR inhibitor, reversed the cytoprotective effects of xanthoxylin. Xanthoxylin protects against alcoholic liver injury through regulating the EGFR/AKT pathway, with concurrent modulation of PPARG and PTGS2. These findings provide compelling evidence for xanthoxylin as a promising therapeutic candidate for ALI and establish a foundation for subsequent preclinical development.
Indexed as
Identifiers
42796515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.